Alan Naylor

COX-2, CB2 and P2X7-immunoreactivities are increased in activated microglial cells/macrophages of multiple sclerosis and amyotrophic lateral sclerosis spinal cord

Y. Yiangou, P. Facer, Pascal F. Durrenberger et al. · BMC Neurology · 2006 · 503 citations · Full text

Oral administration of a potent and selective non‐peptidic BACE‐1 inhibitor decreases β‐cleavage of amyloid precursor protein and amyloid‐β production <i>in vivo</i>

Ishrut Hussain, Julie A. Hawkins, David C. Harrison et al. · Journal of Neurochemistry · 2006 · 198 citations

Molecular Pharmacology, Alzheimer's Disease, Biochemistry +13

Discovery of 2-[(2,4-Dichlorophenyl)amino]- <i>N</i> -[(tetrahydro- 2 <i>H</i> -pyran-4-yl)methyl]-4-(trifluoromethyl)- 5-pyrimidinecarboxamide, a Selective CB2 Receptor Agonist for the Treatment of Inflammatory Pain

Gerard M.P. Giblin, Celestine T. O’Shaughnessy, Alan Naylor et al. · Journal of Medicinal Chemistry · 2007 · 120 citations · Full text

A hyperspectral fluorescence lifetime probe for skin cancer diagnosis

Pieter De Beule, Christopher Dunsby, Neil P. Galletly et al. · Review of Scientific Instruments · 2007 · 93 citations

A potent new class of .kappa.-receptor agonist: 4-substituted 1-(arylacetyl)-2-[(dialkylamino)methyl]piperazines

Alan Naylor, Duncan B. Judd, Jane E. Lloyd et al. · Journal of Medicinal Chemistry · 1993 · 92 citations · Full text

Molecular Pharmacology, Medicinal Chemistry, Kappa-specific Tissue +14